The effect of intravitreal anti-VEGF agents on peripheral wound healing in a rabbit model

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 61-69

  Christoforidis, John ^a   Ricketts, Robert ^a   Pratt, Cedric ^a   Pierce, Jordan ^a   Bean, Scott ^a   Wells, Michael ^a   Zhang, Xiaoli ^b   la Perle, Krista ^b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Anti VEGF; Bevacizumab; Intraocular; Pegaptanib; Ranibizumab; Wound healing

Indexed keywords

BEVACIZUMAB; CD34 ANTIBODY; EOSIN; HEMATOXYLIN; PEGAPTANIB; PLACEBO; RANIBIZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL MODEL; EXPERIMENTAL RABBIT; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PUNCH BIOPSY; QUANTITATIVE ANALYSIS; SKIN INJURY; VASCULAR ENDOTHELIUM; WOUND HEALING;

EID: 84863078521     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S28275     Document Type: Article

References (47)

1. Friedman DS, O'Colmain BJ, Muños T, et al; For the Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
2. Rogers S, McIntosh RL, Cheung N, et al; For the International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117(2):313-319.
3. Blumenkranz MS. New therapy for central retinal vein occlusion: are intravitreal steroids a possible answer? Arch Ophthalmol. 2005;123:259-261.
4. Kempen JH, O'Colmain, Leske MC, et al; For the Eye Diseases Prevalence Research Group: The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol. 2004;122:552-563.
5. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;359(5):427-434.
6. Pouessel D, Culine S. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur Urol. 2008;53(2):376-381.
7. Berry SR, Van Cutsem E, Kretzschmar A, et al. Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: first BEAT. J Clin Oncol. 2008; 26(Suppl 15):abstract 4025.
8. Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009;20:807-815.
9. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor; systematic review and meta-analysis. Am J Kidney Dis. 2007;49(2):186-193.
10. Shah MA, Ilson D, Kelsen DP. Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumabbased therapy. J Clin Oncol. 2005;23(11):2574-2576.
11. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43(3):490-501.
12. Cho YJ, Septimiu DM, Colt HG. Bronchoscopy for bevacizumab-related hemoptysis. Lung Cancer. 2007;56:465-468.
13. Lordick F, Neinitz H, Thelsen J, Sendler A, Sarbia M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys. 2006;64(5):1295-1298.
14. Totlib V, Khaled S, Lapko I, Mar N, Saif MW. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs. 2006;17(10):1227-1229.
15. Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009;62(6):707-709.
16. Zawacki WJ, Walker TG, DeVasher E, et al. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. J Vasc Interv Radiol. 2009;20(5):624-627.
17. Thornton AD, Ravn P, Winslet M, Chester K. Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancer. Br J Surg. 2006;93(12):1456-1463.
18. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005;91(3):173-180.
19. Allegra CJ, Yothers G, O'Connell MJ, et al. Initial Safety Report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer (BEAT). J Clinic Oncol. 2009;27:3385-3390.
20. Bose D, Meric-Bernstam F, Hofstetter W, Reardon DA, Flaherty KT, Ellis LM. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010;11(4):373-382.
21. Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clinic Oncol. 2005;23:4853-4855.
22. Sugrue MM, Purdie DM, Feng S, et al. Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): results from the BRiTE observational cohort study (OCS). Proc Am Soc Clin Oncol. 2008;26(Suppl 15):abstract 4105.
23. Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ; For the CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
24. Cullen KA, Hall MJ, Golosinskiy A. Ambulatory surgery in the United States, 2006. Natl Health Stat Report. 2009;11:1-25.
25. Abramov Y, Golden B, Sullivan M, et al. Histologic characterization of vaginal vs abdominal surgical wound healing in a rabbit model. Wound Repairs Regen. 2007;15(1):80-86.
26. Shrout PE, Fleiss JL. Intraclass correlations: Uses in assessing rater reliability. Psychol Bull. 1979;86:420-428.
27. Hunt T. Wound Healing and Wound Infection: Theory and Surgical Practice. New York: Appleton-Century-Crofts; 1980.
28. Howdieshell TR, Riegner C, Gupta V, Callaway D, Sathyanarayana, McNeil PL. Normoxic wound fluid contains high levels of vascular endothelial growth factor. Ann Surg. 1998;228:707-715.
29. Brown LF, Van De Water L, Harvery VS, Dvorak HF. Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. Am J Pathol. 1988;130:455-465.
30. Breuing K, Eriksson E, Liv P, Miller DR. Healing of partial thickness porcine skin wounds in a liquid environment. J Surg Res. 1992;52:50.
31. Howdieshell TR, Callaway D, Webb WL, et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res. 2001;96:173-182.
32. Rich RM, Rosenfeld PJ, Pulafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26:495-511.
33. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112(6):1035-1047.
34. Csaky K, Do DV. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol. 2009;148(5): 647-656.
35. Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006;113:1508-1521.
36. Heldin CH, Westermark B. Mechanism of action and in-vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.
37. Liekens S, De Clercq E, Neyts J. Angiogenesis: Regulators and clinical applications. Biochem Pharmacol. 2001;61:253-270.
38. Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med. 1999;341:738-746.
39. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of ranibizumab after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726-733.
40. Miyake T, Sawada O, Kakinoki M, et al. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes. Invest Ophthalmol Vis Sci. 2010;51:1606-1608.
41. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114(5): 855-859.
42. Macugen (pegaptanib sodium injection) product information. RX List. The Internet Drug List. Available at: http://www.rxlist.com/macugendrug.htm. Accessed February 11, 2009.
43. Grad S, Ertel W, Keel M, Infanger M, Vonderschmitt DJ, Maly FE. Strongly enhanced serum levels of vascular endothelial growth factor (VEGF) after polytrauma and burn. Clin Chem Lab Med. 1998;36(6): 379-383.
44. Larsson A, Skoldenberg E, Ericson H. Serum and plasma levels of FGF-2 and VEGF in healthy blood donors. Angiogenesis. 2002;4: 107-110.
45. Douzinas E, Betrosian A, Livaditi O, et al. Hypoxemic resuscitation after hemorrhagic shock is accompanied by reduced serum levels of angiopoietin-2. Cytokine. 2009;47(2):82-84.
46. Lin YS, Nguyen C, Medoza JL, et al. Preclinical pharmacokinetics, interspecies scaling and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther. 1999;299:371-378.
47. Watkins RH, D'Angio CT, Ryan RM, Patel A, Maniscalco WM. Differential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injury. Am J Physiol. 1999;276(5 Pt 1):858-867.